Kristen Albright, PharmD, is the CEO of Prokarium, a privately held London-based biotech with the vision of creating living cures for difficult-to-treat cancers. With a successful track record, Kristen played a pivotal role in securing $30 million in funding and spearheading significant synthetic biology R&D collaborations for Prokarium in 2023. Prior to Prokarium, Kristen was an investor at Osage University Partners, where she led several early-stage investments into life sciences companies. Earlier in her career, she worked within business development and M&A at Emergent BioSolutions and Cangene Corporation. Kristen started her industry career at Centocor, a subsidiary of J&J, and earned her Doctor of Pharmacy from the Philadelphia College of Pharmacy and MBA from Saint Joseph’s University.